FAIRFIELD, Conn., May 18, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) introduced the inventor of its Calmare® Pain Therapy Treatment to about 100 attendees, primarily medical professionals, at a symposium in Boston, Mass., yesterday. Several noted physicians described their evidence-based success treating patients suffering from chronic pain associated with cancer and various types of neuropathic ailments.
The Calmare Pain Therapy Conference began with keynote speaker and Calmare's inventor, Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, Italy. Prof. Marineo explained his "Scrambler Therapy," the technology and scientific basis for this revolutionary pain treatment method. Prof. Marineo provided an overview of the history of "electro-analgesia", emphasizing that his "Scrambler Therapy" was the first electro-analgesic methodology to exploit the central nervous system's C-fibers to remodel and eliminate a patient's pain. The "Scrambler Therapy" technology utilizes the "information theory" developed by Claude Shannon at the Massachusetts Institute of Technology (MIT), which is the basis for today's computer technologies in our information age. Previous methods have utilized the more tactile nerve fibers to block pain.
In his discussions with other medical professionals during the day, Prof. Marineo emphasized the importance of physician-patient collaboration in understanding the patient's specific pain prior to successfully treating it with Calmare Pain Therapy. He encouraged his fellow physicians to be guided by the patient in the pain management process. Throughout the day, physicians from the Boston Foundation for Sight, the University of Miami, the University of Wisconsin, and Calmar Pain Relief, LLC, presented evidence-based patient case studies developed from their use of this innovative technology to treat various types of chronic pain. Typically, the patient's pain had been resistant to other treatment methodologies, including powerful narcotic painkillers, with associated adverse side effects.
"This treatment has been life-changing — and life-saving — for some patients," according to Perry Rosenthal, MD; Founding President, Vice Chairman and Scientific Director at the Boston Foundation for Sight, and Assistant Clinical Professor of Ophthalmology, Harvard Medical School; who shared several vignettes about patients he had successfully treated using the Calmare Pain Therapy. According to Dr. Rosenthal, "the cornea is the most powerful pain generator in the body." Having worked with patients suffering from extreme pain involving their eyes, Dr. Rosenthal emphasized just how debilitating chronic pain can be, previously leading some to contemplate suicide as a means of relief … relief that Calmare Pain Therapy now provides.
Salahadin Abdi, MD, Professor and Chief, University of Miami Pain Center, Anesthesiology, Perioperative Medicine & Pain Management; and Toby Campbell, MD; Assistant Professor of Medicine, Hematology & Oncology, University of Wisconsin, Paul J. Carbone Cancer Center; both discussed their clinical trials and shared successes they had in treating patients with Calmare Pain Therapy. Dr. Campbell outlined his upcoming clinical study, which will evaluate the use of Calmare in treating chemotherapy-induced peripheral neuropathy (CIPN), providing details about the specific pain and its impact on cancer patients and survivors, the number of patients to be enrolled, the plans for comparisons with a "placebo" treatment, as well as the anticipated timeline for completion and publication of results.
"I have come to believe that no one should live in pain," stated Stephen J. D'Amato, MD, FACEP; Medical Director, Calmar Pain Relief, LLC; Clinical Assistant Professor of Medicine, Boston University School of Medicine, and Medical Staff, Roger Williams Medical Center; after sharing several evidence-based case studies of patients successfully treated in his Rhode Island clinic. Suffering from chronic and debilitating neuropathic pain, the patients discussed all had their pain relieved with Calmare treatments. "We owe it to our patients to treat them with dignity in attempting to ease their pain. At the very least we should do no harm. This non-invasive treatment does no harm."
"We are privileged and pleased that these doctors have attested to the effectiveness of our Calmare Pain Therapy Treatment by sharing their evidence-based patient successes with the community of physicians attending our symposium," said John B. Nano, CTT's Chairman, President and CEO. "Having Prof. Marineo discuss this innovative technology has provided a unique perspective for physicians to gain a deeper understanding of how the device functions and the treatment's efficacy in relieving patients' pain. We are encouraged by the positive response of this community of medical professionals to both Prof. Marineo and the physicians who presented their evidence-based patient case studies."
With recent media coverage focusing on the negative side effects of morphine and other powerful painkillers, the Calmare device offers physicians an effective and cost-effective alternative for treating high intensity oncologic and neuropathic pain, including pain resistant to opioids and other treatment methodologies. The Calmare Pain Therapy Treatment, with US FDA clearance and European Union CE Certification for sales, is a prime example of CTT's strategy to connect clinical science to patient care. For more information about the Calmare device visit: www.CalmareTT.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.